The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock List
ChartZero.com
ChartZero

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Fri., Jan. 30, 10:56 PM

Slide #16. Auspex Pharmaceuticals, Inc. Secondary Offering

Company: Auspex Pharmaceuticals, Inc. (NASDAQ:ASPX)
Date announced: 1/21/2015
Shares Offered: 4,000,000
Date of Pricing: 1/23/2015
Price Per Share: $56.50
Secondary Offering Details: Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a biopharmaceutical company dedicated to developing innovative medicines for people with movement disorders and other rare diseases, today announced that it has commenced an underwritten public offering of 4,000,000 shares of its common stock. The offering is expected to consist of 3,000,000 shares of common stock to be offered by Auspex and 1,000,000 shares of common stock to be offered by selling stockholders. In addition, the company is expected to grant the underwriters of the offering an option for a period of 30 days to purchase from Auspex up to an additional 600,000 shares of common stock, on the same terms and conditions. - updated 1/23 - Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a biopharmaceutical company dedicated to developing innovative medicines for people with movement disorders and other rare diseases, today announced the pricing of its underwritten public offering of 4,000,000 shares of its common stock at a price to the public of $56.50 per share. Auspex is offering 3,000,000 shares of common stock and certain existing stockholders of Auspex are offering 1,000,000 shares of common stock. The gross proceeds to Auspex from this offering are expected to be approximately $169.5 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Auspex. In addition, the underwriters of the offering have been granted a 30-day option to purchase from Auspex up to an additional 600,000 shares of common stock, on the same terms and conditions. Auspex will not receive any proceeds from the sale of the shares by the selling stockholders. J.P. Morgan Securities LLC is sole book-running manager for the offering. In addition, Stifel and BMO Capital Markets Corp. are acting as co-lead managers, and Robert W. Baird & Co. Incorporated and William Blair and Company, L.L.C., are acting as co-managers. Maxim Group LLC is acting as an advisor to Auspex.

Auspex Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of medicines for the treatment of orphan diseases. Co.'s pipeline includes product candidates to address medical needs in hyperkinetic movement disorders, such as chorea associated with Huntington's disease, and tardive dyskinesia and Tourette syndrome. Co.'s primary product candidate, SD-809, is in a registration clinical trial for the treatment of chorea (abnormal involuntary movements) associated with Huntington's disease. Co.'s portfolio also includes other deuterium-containing compounds that are at various stages of development, including SD-254, SD-560, SD-970, and SD-900.
Open the ASPX Page at The Online Investor »

Company Name:  Auspex Pharmaceuticals Inc
Website:  www.auspexpharma.com
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding ASPX:  16
Total Market Value Held by ETFs:  $38.46M
Total Market Capitalization:  $1.68B
% of Market Cap. Held by ETFs:  2.30%
 

Open the ASPX Page at The Online Investor (in a new window) »

January 30, 2015    10:56 PM Eastern
Quotes delayed 20 minutes



Strong Buy (4.00 out of 4)
92nd percentile
(ranked higher than approx. 92% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | www.TheOnlineInvestor.com | Copyright © 1998 - 2015, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.